Any failure to raise capital as and when needed would compromise our ability to execute our business plan and may cause us to undertake cost containment measures and/or significantly delay, scale back or discontinue the development of some of our programs.

filing / Aug 10, 2026 / receipt

As part of cost containment measures undertaken by us, early discovery and preclinical programs have been deprioritized with less personnel and funding allocated to advancing these programs.

filing / Aug 10, 2026 / receipt

The increase of $1.2 million for the six months ended June 30, 2026 was primarily due to a $8.0 million impairment expense of equipment, leasehold improvements and right-of-use assets in June 2026, offset by a $6.8 million decrease in personnel expenses, including $4.8 million in severance expenses from the reduction in force incurred in March 2025.

filing / Aug 10, 2026 / receipt

• a $0.6 million decrease in personnel costs primarily from lower salaries and wages and share based compensation expense recognized due to lower headcount as a result of the reduction in force in March 2025.

filing / Aug 10, 2026 / receipt

Any failure to raise capital as and when needed would compromise our ability to execute our business plan and may cause us to undertake cost containment measures and/or significantly delay, scale back or discontinue the development of some of our programs.

filing / May 12, 2026 / receipt

As part of cost containment measures undertaken by us, early discovery and preclinical programs have been deprioritized with less personnel and funding allocated to advancing these programs.

filing / May 12, 2026 / receipt

The decrease of $6.5 million for the three months ended March 31, 2026 was primarily due to a $6.3 million decrease in personnel expenses, including $5.1 million in severance expenses from the reduction in force incurred in March 2025, and a $0.2 million decrease in facilities expenses allocated to general and administrative expenses.

filing / May 12, 2026 / receipt

• a $1.5 million decrease in personnel costs primarily from lower salaries and wages and share based compensation expense recognized due to lower headcount as a result of the reduction in force in March 2025.

filing / May 12, 2026 / receipt

Test Posting | {"ats": "greenhouse", "city": null, "state": null, "job_id": "4551155008", "remote": true, "category": "other", "function": "other", "location": "Remote", "job_title": "Test Posting", "

company_statement / Feb 24, 2025 / receipt